Nasal lavage CCL24 levels correlate with eosinophils trafficking and symptoms in chronic sino-nasal eosinophilic inflammation

Rhinology

Volumn 49, Issue 2, 2011, Pages 174-179

  de Corso, Eugenio ^a   Baroni, Silvia ^a   Romitelli, Federica ^a   Luca, Liberati ^a   Di Nardo, Walter ^a   Passali, Giulio Cesare ^a   Paludetti, Gaetano ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

CCL24; Eosinophilic chronic rhinosinusitis; Eotaxin 2; NARES; Nasal lavage; Nasal polyps

Indexed keywords

EOTAXIN 2;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL COUNT; CHEMISTRY; CHILD; CHRONIC DISEASE; CROSS-SECTIONAL STUDY; EOSINOPHILIA; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NOSE MUCOSA; NOSE MUCUS; RHINITIS;

ADOLESCENT; ADULT; AGED; CELL COUNT; CHEMOKINE CCL24; CHILD; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; EOSINOPHILIA; FEMALE; HUMANS; MALE; MIDDLE AGED; NASAL LAVAGE FLUID; NASAL MUCOSA; RHINITIS; YOUNG ADULT;

EID: 80051568063     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: 10.4193/Rhino10.133     Document Type: Article

References (38)

1. Baumann I, Blumenstock G, Zalaman IM et al. Impact of gender, age, and comorbidities on quality of life in patients with chronic rhinosinusitis. Rhinology 2007; 45: 268-272.
2. Riechelmann H, Deutschle T, Friemel E, Gross HJ, Bachem M. Biological markers in nasal secretions. Eur Resp J. 2003; 21: 600-605.
3. Carr WW, Nelson MR, Hadley JA. Managing rhinitis: strategies for improved patient outcomes. Allergy Asthma Proc. 2008; 29: 349-357.
4. Saigusa H, Miyazawa T, Suzuki M, Iino Y, Kodera K. Eosinophil chemoattractants and related factors in nasal polyps. Nippon Jibiinkoka Gakkai Kaiho 2006; 109: 774-780.
5. Eliashar R, Levi Schaffer F. The role of the eosinophil in nasal disease. Curr Opinion Otolaryngol Head and Neck Surg. 2005; 13: 171-175.
6. Pawliczak R, Lewandowska-Polak A, Kpwalski ML. Pathogenesis of nasal polyps: an update. Curr Allergy Asthma Rep. 2005; 5: 463-471.
7. Tos M, Mogensen C. Pathogenesis of nasal polyps. Rhinology 1977; 15: 87-95.
8. Meyer JE, Bartels J, Görögh T et al. The role of RANTES in nasal polyposis. Am J Rhinol. 2005; 19: 15-20.
9. Meyer-Hoffert U, Lezcano-Meza D, Bartels J, Montes-Vizuet AR, Schröder JM, Teran LM. Th2-and to a lesser extent Th1-type cytokines upregulate the production of both CXC (IL-8 and groalpha) and CC (RANTES, eotaxin, eotaxin-2, MCP-3 and MCP-4) chemokines in human airway epithelial cells. Int Arch Allergy Immunol. 2003; 131: 264-271.
10. Olze H, Förster U, Zuberbier T, Morawietz L, Luger EO. Eosinophilic nasal polyps are a rich source of eotaxin, eotaxin-2 and eotaxin-3. Rhinology. 2006; 44: 145-150.
11. Molinaro RJ, Bernstein JM, Koury ST. Localization and quantitation of eotaxin mRNA in human nasal polyps. Immunol Invest. 2003; 32: 143-154.
12. Fan GK, Wang H, Takenaka H. Eosinophil infiltration and activation in nasal polyposis. Acta Otolaryngol. 2007; 127: 521-526.
13. Pods R, Ross D, Van Hülst, Rudack C, Maune S. RANTES, 5eotaxin and eotaxin-2 expression and production in patients with aspirin triad. Allergy. 2003; 58: 1165-1170.
14. Yao T, Kojima Y, Koyanagi A et al. Eotaxin-1, -2, and -3 immunoreactivity and protein concentration in the nasal polyps of eosinophilic chronic rhinosinusitis patients. Laryngoscope. 2009; 119: 1053-1059.
15. Salib RJ, Lau LC, Howarth PH. Nasal lavage fluid concentrations of eotaxin-1 (CCL11) in naturally occurring allergic rhinitis: relationship to disease activity, nasal luminal eosinophil influx, and plasma protein exudation. Clin Exp Allergy. 2005; 35: 995-1002.
16. Rondón C, Doña I, López S, Campo P, Romero J, Torres MJ, Mayorga C, Blanca M. Seasonal idiopathic rhinitis with local inflammatory response and specific IgE in absence of systemic response. Allergy. 2008; 63: 1352-1358.
17. Rondón C, Doña I, Torres MJ, Campo P, Blanca M. Evolution of patients with nonallergic rhinitis supports conversion to allergic rhinitis. J Allergy Clin Immunol. 2009; 123: 1098-1102.
18. Noah TL, Tudor GE, Ivins SS Murphy PC, Peden DB, Henderson FW. Repeated measurement of nasal lavage fluid chemokines in school-age children with asthma. Ann Allergy Asthma Immunol. 2006; 96: 304-310.
19. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63 Suppl 86: 8-160.
20. Fokkens W, Lund V, Mullol J. European Position Paper on Rhinosinusitis and Nasal Polyps group 2007. Rhinology 2007; 20: 1-136.
21. Belda J, Paramenswaran K, Keith PK, Hargreave FE. Repeatability and validity of cell and fluid phase measurements in nasal fluid: a comparison of two methods of nasal lavage. Clin Exp Allergy. 2001; 31: 1111-1115.
22. Besançon-Watelet C, Béné MC, Montagne P, Faure GC, Jankowski R. Eosinophilia and cell activation mediators in nasal secretions. Laryngoscope. 2002; 112: 43-46.
23. Nikasinovic-Fournier L, Just J, et al. Nasal lavage as a tool for the assessment of upper-airway inflammation in adults and children. J Lab Clin Med. 2002; 139: 173-180.
24. Pawankar R, Nonaka M. Inflammatory mechanisms and remodeling in chronic rhinosinusitis and nasal polyps. Curr Allergy Asthma Rep. 2007; 7: 202-208.
25. Riechelmann H, Deutschle T, Rozsasi A, Keck T, Polzehl D, Bürner H. Nasal biomarker profiles in acute and chronic rhinosinusitis. Clin Exp Allergy. 2005; 35: 1186-1191.
26. Otto BA, Wenzel SE. The role of cytokines in chronic rhinosinusitis with nasal polyps. Curr Opin Otolaryngol Head Neck Surg. 2008; 16: 270-274.
27. Hemelaers L, Henket M, Sele J, Bureau F, Louis R. Cysteinyl-leukotrienes contribute to sputum eosinophil chemotactic activity in asthmatics. Allergy. 2006; 61: 136-139.
28. Kramer MF, Burow G, Pfrogner E, Rasp G. In vitro diagnosis of chronic nasal inflammation. Clin Exp Allergy. 2004; 34: 1086-1092.
29. Shin SH, Lee SH, Jeong HS, Kita H. The effect of nasal polyp epithelial cells on eosinophil activation. Laryngoscope. 2003; 113: 1374-1377.
30. Haasen D, Merk S, Seither P, Martyres D, Hobbie S, Heilker R. Pharmacological profiling of chemokine receptor-directed compounds using high-content screening. J Biomol Screen. 2008; 13: 40-53.
31. Haley KJ, Sunday ME, Porrata Y, et al. Ontogeny of the eotaxins in human lung. Am J Physiol Lung Cell Mol Physiol. 2008; 294: 214-224.
32. Ben S, Li X, Xu F, et al. Treatment with anti-CC chemokine receptor 3 monoclonal antibody or dexamethasone inhibits the migration and differentiation of bone marrow CD34 progenitor cells in an allergic mouse model. Allergy. 2008; 63: 1164-1176.
33. Schaefer D, Meyer JE, Pods R, et al. Endothelial and epithelial expression of eotaxin-2 (CCL24) in nasal polyps. Int Arch Allergy Immunol. 2006; 140: 205-214.
34. Lezcano-Meza D, Dávila-Dávila B, Vega-Miranda A, Negrete-García MC, Teran LM. Interleukine IL-4 and to a lesser extent either IL-13 or interferon-gamma regulate the production of eotaxin-2/CCL24 in nasal polyps. Allergy. 2003; 58: 1011-1017.
35. Ravensberg AJ, Ricciardolo FL, van Schadewijk A, et al. Eotaxin-2 and eotaxin-3 expression is associated with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge. J Allergy Clin Immunol. 2005; 115: 779-785.
36. Plewako H, Holmberg K, Oancea I, Gotlib T, Samoli ski B, Rak S. A follow-up study of immunotherapytreated birch-allergic patients: effect on the expression of chemokines in the nasal mucosa. Clin Exp Allergy. 2008; 38: 1124-1131.
37. Su YC, Rolph MS, Hansbro NG, Mackay CR, Sewell WA. Granulocyte-macrophage colonystimulating factor is required for bronchial eosinophilia in a murine model of allergic airway inflammation. J Immunol. 2008; 180: 2600-2607.
38. Yoshifuku K, Matsune S, Ohori J, Sagara Y, Fukuiwa T, Kurono Y. IL-4 and TNF-alpha increased the secretion of eotaxin from cultured fibroblasts of nasal polyps with eosinophil infiltration. Rhinology. 2007; 45: 235-241